![Emyr Lloyd-Evans DPhil (Oxon)](https://profiles-cardiff.imgix.net/attachments/1106?w=200&h=200&auto=format&crop=faces&fit=crop&q=90")
Professor Emyr Lloyd-Evans
(he/him)
DPhil (Oxon)
- Welsh speaking
- Available for postgraduate supervision
Teams and roles for Emyr Lloyd-Evans
Deputy Director, Medicines Discovery Institute
School of Biosciences
Overview
Research overview
My group is interested in identifying and treating the mechanisms leading to cell death in the lysosomal storage disorders, which are the most common cause of childhood neurodegenerative disease. We are also interested in determining the similarities between lysosomal diseases and associated neurodegenerative diseases of ageing, including Alzheimer's, Parkinson's and Huntington's, where we believe there are possibilities to treat similar underlying disease mechanisms. We are particularly interested in lysosomal Ca2+ signalling, endocytosis, autophagy and lysosomal protein (enzymes, channels and transporters) function. Our aim is to identify key disease relevant targets that can be interrogated by robust assays in order to screen and identify novel disease modifying small molecule tool compounds. Structural biology and medicinal chemistry are then employed to generate and deliver improved small molecule medicines that are tested in novel cellular disease models. My group has a track record of going from bench to bedside, and of collaborating with industry and patient organisation partners to deliver novel therapies for these devastating diseases.
Publication
2025
- Best, H. L. et al. 2025. Niemann-Pick C-like endo-lysosomal dysfunction in DHDDS patient cells, a congenital disorder of glycosylation, can be treated with miglustat. International Journal of Molecular Sciences 26 (4) 1471. (10.3390/ijms26041471)
- Kirkham, E. et al., 2025. Lysosomal pH measurements via dual-imaging microscopy. In: Hughes, S. M. and Basak, I. eds. Lysosomes: Methods and Protocols. Vol. 2976, Methods in Molecular Biology New York, New York, USA: , pp.11-24. (10.1007/978-1-0716-4844-5_2)
- Reeks, J. et al., 2025. High throughput cryo-EM provides structural understanding for modulators of the lysosomal ion channel TRPML1. Structure 33 (8), pp.1374-1385. (10.1016/j.str.2025.05.014)
2024
- Cubitt, J. et al. 2024. Beware of N-Benzoyloxybenzamides. Molecules 29 (21) 5143. (10.3390/molecules29215143)
2023
- Best, H. et al. 2023. The Batten disease associated protein CLN3 is required for the efflux of lysosomal K. Presented at: 19th Annual WORLDSymposium™ 2023 Orlando, Florida 21-26 February 2023. Vol. 138.Vol. 2. Elsevier. , pp.47-47. (10.1016/j.ymgme.2022.107030)
- Best, H. L. et al. 2023. Disease phenotypes present in CLN7 patient fibroblasts are improved following treatment to reduce glycosphingolipid synthesis.. Presented at: 19th Annual WORLDSymposium™ 2023 Orlando, Florida 21-26 February 2023. Vol. 138.Vol. 2. Elsevier. , pp.17. (10.1016/j.ymgme.2022.107029)
- Best, H. L. et al. 2023. The role of glycoconjugates as receptors for insecticidal proteins. FEMS Microbiology Reviews 47 (4)(10.1093/femsre/fuad026)
- Cook, S. R. et al. 2023. Investigating lysosomal and cellular phenotypes of the lysosomal disorder cystinosis. Presented at: 19th Annual WORLDSymposium™ 2023 Orlando, Florida 21-26 February 2023. Vol. 138.Vol. 2. Elsevier. , pp.28-28. (10.1016/j.ymgme.2022.107061)
- Cook, S. R. and Lloyd-Evans, E. 2023. Comparing the lysosomal biotoxicity of iron oxide nanoparticles for improved lysosomal purification. Presented at: 19th Annual WORLDSymposiumTM Orlando, Florida 21-26 February 2023. Vol. 138.Vol. 2. Elsevier. , pp.28-29. (10.1016/j.ymgme.2022.107062)
- Fenn, G. D. et al. 2023. Development of a novel anthraquinone-derived fluorescent lysosomal probe. Molecular Genetics and Metabolism 138 (2) 107097. (10.1016/j.ymgme.2022.107097)
- Fenn, G. D. , Lloyd-Evans, E. and Waller-Evans, H. 2023. Investigation of cannabidiol as a potential therapeutic in Niemann-Pick disease. Presented at: 19th Annual WORLDSymposium™ 2023 Orlando, Florida 21-26 February 2023. Vol. 138.Vol. 2. Elsevier. , pp.42-42. (10.1016/j.ymgme.2022.107098)
- Honeybun, L. , Waller-Evans, H. and Lloyd-Evans, E. 2023. Unbiased phenotypic drug screen for CLN3 disease. Presented at: 19th Annual WORLDSymposium™ 2023 Orlando, Florida 21-26 February 2023. Vol. 138.Vol. 2. Elsevier. , pp.167-167. (10.1016/j.ymgme.2022.107150)
- Lloyd-Evans, E. et al. 2023. Glycosphingolipid reduction with miglustat as a therapeutic strategy for CLN3 and other neuronal ceroid lipofuscinoses.. Presented at: 19th Annual WORLDSymposium™ 2023 Orlando, Florida 21-26 February 2023. Vol. 138.Vol. 2. Elsevier. , pp.84. (10.1016/j.ymgme.2022.107212)
- Lloyd-Evans, E. and Evans, C. 2023. Deciphering the various mechanisms of action of miglustat in the lysosomal disorders.. Presented at: 19th Annual WORLDSymposiumTM Orlando, Florida 21-26 February 2023. Vol. 138.Vol. 2. Elsevier. , pp.84. (10.1016/j.ymgme.2022.107213)
- Somogyi, A. et al., 2023. The synthetic TRPML1 agonist ML-SA1 rescues Alzheimer-related alterations of the endosomal-autophagic-lysosomal system. Journal of Cell Science 136 (6) jcs259875. (10.1242/jcs.259875)
- Waller-Evans, H. et al. 2023. Filipin composition and imaging modality dramatically affect cellular cholesterol visualisation with implications for assessing cholesterol levels and localisation across the lysosomal disorders. Presented at: 19th Annual WORLDSymposium™ 2023 Orlando, Florida 21-26 February 2023. Vol. 138.Vol. 2. Elsevier. , pp.133. (10.1016/j.ymgme.2022.107352)
- Waller-Evans, H. et al. 2023. Measuring ion flux via lysosomal channels: Primary and secondary assays for drug discovery across the lysosomal disorders. Presented at: 19th Annual WORLDSymposium™ 2023 Orlando, Florida 21-26 February 2023. Vol. 138.Vol. 2. Elsevier. , pp.133-134. (10.1016/j.ymgme.2022.107353)
- Williamson, L. J. et al. 2023. Structure of the Lysinibacillus sphaericus Tpp49Aa1 pesticidal protein elucidated from natural crystals using MHz-SFX. Proceedings of the National Academy of Sciences 120 (49) e2203241120. (10.1073/pnas.2203241120)
2022
- Best, H. L. et al. 2022. The crystal structure of Bacillus thuringiensis Tpp80Aa1 and its interaction with galactose-containing glycolipids. Toxins 14 (12) 863. (10.3390/toxins14120863)
2021
- Maguire, E. et al. 2021. PIP2 depletion and altered endocytosis caused by expression of Alzheimer's disease-protective variant PLCγ2 R522. EMBO Journal 40 (17) e105603. (10.15252/embj.2020105603)
2020
- Badell Grau, R. A. et al. 2020. Investigating the prevalence of reactive online searching in the COVID-19 pandemic. Journal of Medical Internet Research 22 (10) e19791. (10.2196/19791)
- Cook, S. R. et al. 2020. Detrimental effect of zwitterionic buffers on lysosomal homeostasis in cell lines and iPSC-derived neurons. AMRC Open Research 2 21. (10.12688/amrcopenres.12903.1)
- Cook, S. R. et al. 2020. Visualisation of cholesterol and ganglioside GM1 in zebrafish models of Niemann-Pick type C disease and Smith-Lemli-Opitz syndrome using light sheet microscopy. Histochemistry and Cell Biology 154 , pp.565-578. (10.1007/s00418-020-01925-2)
- Day, A. H. et al. 2020. Targeted cell imaging properties of a deep red luminescent iridium(III) complex conjugated with a c-Myc signal peptide. Chemical Science 11 (6), pp.1599-1606. (10.1039/C9SC05568A)
- Lloyd-Evans, E. and Waller-Evans, H. 2020. Biosynthesis and signalling functions of central and peripheral nervous system neurosteroids in health and disease. Essays in Biochemistry 64 (3), pp.591-606. (10.1042/EBC20200043)
2019
- Balogi, Z. et al., 2019. Hsp70 interactions with membrane lipids regulate cellular functions in health and disease. Progress in Lipid Research 74 , pp.18-30. (10.1016/j.plipres.2019.01.004)
- Carreira, A. et al., 2019. Mammalian sphingoid bases: Biophysical, physiological and pathological properties. Progress in Lipid Research 75 100988. (10.1016/j.plipres.2019.100988)
2018
- Lange, J. et al., 2018. Compromised astrocyte function and survival negatively impact neurons in infantile neuronal ceroid lipofuscinosis. Acta Neuropathologica Communications 6 74. (10.1186/s40478-018-0575-4)
- Morimoto, M. et al., 2018. Bi-allelic CCDC47 variants cause a disorder characterized by woolly hair, liver dysfunction, dysmorphic features, and global developmental delay. American Journal of Human Genetics 103 (5), pp.794-807. (10.1016/j.ajhg.2018.09.014)
2017
- Fineran, P. et al., 2017. Pathogenic mycobacteria achieve cellular persistence by inhibiting the Niemann-Pick Type C disease cellular pathway. Wellcome Open Research 1 18. (10.12688/wellcomeopenres.10036.2)
2016
- Lloyd-Evans, E. 2016. On the move, lysosomal CAX drives Ca2+ transport and motility. Journal of cell biology 212 (7), pp.755-757. (10.1083/jcb.201603037)
- Lloyd-Evans, E. and Haslett, L. 2016. The lysosomal storage disease continuum with ageing-related neurodegenerative disease. Ageing Research Reviews 32 , pp.104-121. (10.1016/j.arr.2016.07.005)
2015
- Chandrachud, U. et al., 2015. Unbiased cell-based screening in a neuronal cell model of Batten Disease highlights an interaction between Ca2+Homeostasis, autophagy, and CLN3 protein function. Journal of Biological Chemistry 290 (23), pp.14361-14380.. (10.1074/jbc.M114.621706)
- Lee, J. et al., 2015. Presenilin 1 maintains Lysosomal Ca2+ homeostasis via TRPML1 by regulating vATPase-mediated lysosome acidification. Cell Reports 12 (9), pp.1430-1444. (10.1016/j.celrep.2015.07.050)
- Oswald, M. C. W. et al., 2015. Identification of dietary alanine toxicity and trafficking dysfunction in a Drosophila model of hereditary sensory and autonomic neuropathy type 1. Human Molecular Genetics 24 (24), pp.6899-6909. (10.1093/hmg/ddv390)
- Walker, M. W. and Lloyd-Evans, E. 2015. A rapid method for the preparation of ultrapure, functional lysosomes using functionalized superparamagnetic iron oxide nanoparticles. Methods in Cell Biology 126 , pp.21-43. (10.1016/bs.mcb.2014.10.019)
- Waller-Evans, H. and Lloyd-Evans, E. 2015. Regulation of TRPML1 function. Biochemical Society Transactions 43 (3), pp.442-446. (10.1042/BST20140311)
2014
- Platt, F. M. et al., 2014. Disorders of cholesterol metabolism and their unanticipated convergent mechanisms of disease. Annual Review of Genomics and Human Genetics 15 (1), pp.173-194. (10.1146/annurev-genom-091212-153412)
2011
- Lloyd-Evans, E. and Platt, F. M. 2011. Lysosomal Ca2+ homeostasis: Role in pathogenesis of lysosomal storage diseases. Cell Calcium 50 (2), pp.200-205. (10.1016/j.ceca.2011.03.010)
- Morgan, A. J. et al. 2011. Molecular mechanisms of endolysosomal Ca2+ signalling in health and disease. Biochemical Journal 439 (3), pp.349-374. (10.1042/BJ20110949)
2010
- Lloyd-Evans, E. and Platt, F. M. 2010. Lipids on trial: The search for the offending metabolite in Niemann-Pick type C disease. Traffic 11 (4), pp.419-428. (10.1111/j.1600-0854.2010.01032.x)
- Lloyd-Evans, E. et al. 2010. Endolysosomal calcium regulation and disease.. Biochemical Society Transactions 38 (6), pp.1458-1464. (10.1042/BST0381458)
- Ruas, M. et al., 2010. Purified TPC isoforms form NAADP receptors with distinct roles for Ca2+ signaling and endolysosomal trafficking. Current Biology 20 (8), pp.703-709. (10.1016/j.cub.2010.02.049)
2008
- Elliot-Smith, E. et al., 2008. Beneficial effects of substrate reduction therapy in a mouse model of GM1 gangliosidosis. Molecular Genetics and Metabolism 94 (2), pp.204-211. (10.1016/j.ymgme.2008.02.005)
- Lloyd-Evans, E. et al. 2008. Niemann-Pick disease type C1 is a sphingosine storage disease that causes deregulation of lysosomal calcium. Nature Medicine 14 (11), pp.1247-1255. (10.1038/nm.1876)
2005
- Pelled, D. et al., 2005. Enhanced calcium release in the acute neuronopathic form of Gaucher disease. Neurobiology of Disease 18 (1), pp.83-88. (10.1016/j.nbd.2004.09.004)
2004
- Lachmann, R. H. et al., 2004. Treatment with miglustat reverses the lipid-trafficking defect in Niemann–Pick disease type C. Neurobiology of Disease 16 (3), pp.654-658. (10.1016/j.nbd.2004.05.002)
- Vruchte, D. T. et al., 2004. Accumulation of glycosphingolipids in Niemann-Pick C disease disrupts endosomal transport. Journal of Biological Chemistry 279 (25), pp.26167-26175. (10.1074/jbc.M311591200)
2003
- Lloyd-Evans, E. et al. 2003. Glucosylceramide and glucosylsphingosine modulate calcium mobilization from brain microsomes via different mechanisms. Journal of Biological Chemistry 278 (26), pp.23594-23599. (10.1074/jbc.M300212200)
- Lloyd-Evans, E. et al. 2003. Lyso-glycosphingolipids mobilize calcium from brain microsomes via multiple mechanisms. Biochemical Journal 375 (3), pp.561-565. (10.1042/BJ20030613)
- Pelled, D. et al., 2003. Inhibition of calcium uptake via the sarco/endoplasmic reticulum Ca2+-ATPase in a mouse model of Sandhoff disease and prevention by treatment with N-Butyldeoxynojirimycin. Journal of Biological Chemistry 278 (32), pp.29496-29501. (10.1074/jbc.M302964200)
Articles
- Badell Grau, R. A. et al. 2020. Investigating the prevalence of reactive online searching in the COVID-19 pandemic. Journal of Medical Internet Research 22 (10) e19791. (10.2196/19791)
- Balogi, Z. et al., 2019. Hsp70 interactions with membrane lipids regulate cellular functions in health and disease. Progress in Lipid Research 74 , pp.18-30. (10.1016/j.plipres.2019.01.004)
- Best, H. L. et al. 2025. Niemann-Pick C-like endo-lysosomal dysfunction in DHDDS patient cells, a congenital disorder of glycosylation, can be treated with miglustat. International Journal of Molecular Sciences 26 (4) 1471. (10.3390/ijms26041471)
- Best, H. L. et al. 2023. The role of glycoconjugates as receptors for insecticidal proteins. FEMS Microbiology Reviews 47 (4)(10.1093/femsre/fuad026)
- Best, H. L. et al. 2022. The crystal structure of Bacillus thuringiensis Tpp80Aa1 and its interaction with galactose-containing glycolipids. Toxins 14 (12) 863. (10.3390/toxins14120863)
- Carreira, A. et al., 2019. Mammalian sphingoid bases: Biophysical, physiological and pathological properties. Progress in Lipid Research 75 100988. (10.1016/j.plipres.2019.100988)
- Chandrachud, U. et al., 2015. Unbiased cell-based screening in a neuronal cell model of Batten Disease highlights an interaction between Ca2+Homeostasis, autophagy, and CLN3 protein function. Journal of Biological Chemistry 290 (23), pp.14361-14380.. (10.1074/jbc.M114.621706)
- Cook, S. R. et al. 2020. Detrimental effect of zwitterionic buffers on lysosomal homeostasis in cell lines and iPSC-derived neurons. AMRC Open Research 2 21. (10.12688/amrcopenres.12903.1)
- Cook, S. R. et al. 2020. Visualisation of cholesterol and ganglioside GM1 in zebrafish models of Niemann-Pick type C disease and Smith-Lemli-Opitz syndrome using light sheet microscopy. Histochemistry and Cell Biology 154 , pp.565-578. (10.1007/s00418-020-01925-2)
- Cubitt, J. et al. 2024. Beware of N-Benzoyloxybenzamides. Molecules 29 (21) 5143. (10.3390/molecules29215143)
- Day, A. H. et al. 2020. Targeted cell imaging properties of a deep red luminescent iridium(III) complex conjugated with a c-Myc signal peptide. Chemical Science 11 (6), pp.1599-1606. (10.1039/C9SC05568A)
- Elliot-Smith, E. et al., 2008. Beneficial effects of substrate reduction therapy in a mouse model of GM1 gangliosidosis. Molecular Genetics and Metabolism 94 (2), pp.204-211. (10.1016/j.ymgme.2008.02.005)
- Fenn, G. D. et al. 2023. Development of a novel anthraquinone-derived fluorescent lysosomal probe. Molecular Genetics and Metabolism 138 (2) 107097. (10.1016/j.ymgme.2022.107097)
- Fineran, P. et al., 2017. Pathogenic mycobacteria achieve cellular persistence by inhibiting the Niemann-Pick Type C disease cellular pathway. Wellcome Open Research 1 18. (10.12688/wellcomeopenres.10036.2)
- Lachmann, R. H. et al., 2004. Treatment with miglustat reverses the lipid-trafficking defect in Niemann–Pick disease type C. Neurobiology of Disease 16 (3), pp.654-658. (10.1016/j.nbd.2004.05.002)
- Lange, J. et al., 2018. Compromised astrocyte function and survival negatively impact neurons in infantile neuronal ceroid lipofuscinosis. Acta Neuropathologica Communications 6 74. (10.1186/s40478-018-0575-4)
- Lee, J. et al., 2015. Presenilin 1 maintains Lysosomal Ca2+ homeostasis via TRPML1 by regulating vATPase-mediated lysosome acidification. Cell Reports 12 (9), pp.1430-1444. (10.1016/j.celrep.2015.07.050)
- Lloyd-Evans, E. 2016. On the move, lysosomal CAX drives Ca2+ transport and motility. Journal of cell biology 212 (7), pp.755-757. (10.1083/jcb.201603037)
- Lloyd-Evans, E. and Haslett, L. 2016. The lysosomal storage disease continuum with ageing-related neurodegenerative disease. Ageing Research Reviews 32 , pp.104-121. (10.1016/j.arr.2016.07.005)
- Lloyd-Evans, E. et al. 2008. Niemann-Pick disease type C1 is a sphingosine storage disease that causes deregulation of lysosomal calcium. Nature Medicine 14 (11), pp.1247-1255. (10.1038/nm.1876)
- Lloyd-Evans, E. et al. 2003. Glucosylceramide and glucosylsphingosine modulate calcium mobilization from brain microsomes via different mechanisms. Journal of Biological Chemistry 278 (26), pp.23594-23599. (10.1074/jbc.M300212200)
- Lloyd-Evans, E. et al. 2003. Lyso-glycosphingolipids mobilize calcium from brain microsomes via multiple mechanisms. Biochemical Journal 375 (3), pp.561-565. (10.1042/BJ20030613)
- Lloyd-Evans, E. and Platt, F. M. 2010. Lipids on trial: The search for the offending metabolite in Niemann-Pick type C disease. Traffic 11 (4), pp.419-428. (10.1111/j.1600-0854.2010.01032.x)
- Lloyd-Evans, E. and Platt, F. M. 2011. Lysosomal Ca2+ homeostasis: Role in pathogenesis of lysosomal storage diseases. Cell Calcium 50 (2), pp.200-205. (10.1016/j.ceca.2011.03.010)
- Lloyd-Evans, E. and Waller-Evans, H. 2020. Biosynthesis and signalling functions of central and peripheral nervous system neurosteroids in health and disease. Essays in Biochemistry 64 (3), pp.591-606. (10.1042/EBC20200043)
- Lloyd-Evans, E. et al. 2010. Endolysosomal calcium regulation and disease.. Biochemical Society Transactions 38 (6), pp.1458-1464. (10.1042/BST0381458)
- Maguire, E. et al. 2021. PIP2 depletion and altered endocytosis caused by expression of Alzheimer's disease-protective variant PLCγ2 R522. EMBO Journal 40 (17) e105603. (10.15252/embj.2020105603)
- Morgan, A. J. et al. 2011. Molecular mechanisms of endolysosomal Ca2+ signalling in health and disease. Biochemical Journal 439 (3), pp.349-374. (10.1042/BJ20110949)
- Morimoto, M. et al., 2018. Bi-allelic CCDC47 variants cause a disorder characterized by woolly hair, liver dysfunction, dysmorphic features, and global developmental delay. American Journal of Human Genetics 103 (5), pp.794-807. (10.1016/j.ajhg.2018.09.014)
- Oswald, M. C. W. et al., 2015. Identification of dietary alanine toxicity and trafficking dysfunction in a Drosophila model of hereditary sensory and autonomic neuropathy type 1. Human Molecular Genetics 24 (24), pp.6899-6909. (10.1093/hmg/ddv390)
- Pelled, D. et al., 2003. Inhibition of calcium uptake via the sarco/endoplasmic reticulum Ca2+-ATPase in a mouse model of Sandhoff disease and prevention by treatment with N-Butyldeoxynojirimycin. Journal of Biological Chemistry 278 (32), pp.29496-29501. (10.1074/jbc.M302964200)
- Pelled, D. et al., 2005. Enhanced calcium release in the acute neuronopathic form of Gaucher disease. Neurobiology of Disease 18 (1), pp.83-88. (10.1016/j.nbd.2004.09.004)
- Platt, F. M. et al., 2014. Disorders of cholesterol metabolism and their unanticipated convergent mechanisms of disease. Annual Review of Genomics and Human Genetics 15 (1), pp.173-194. (10.1146/annurev-genom-091212-153412)
- Reeks, J. et al., 2025. High throughput cryo-EM provides structural understanding for modulators of the lysosomal ion channel TRPML1. Structure 33 (8), pp.1374-1385. (10.1016/j.str.2025.05.014)
- Ruas, M. et al., 2010. Purified TPC isoforms form NAADP receptors with distinct roles for Ca2+ signaling and endolysosomal trafficking. Current Biology 20 (8), pp.703-709. (10.1016/j.cub.2010.02.049)
- Somogyi, A. et al., 2023. The synthetic TRPML1 agonist ML-SA1 rescues Alzheimer-related alterations of the endosomal-autophagic-lysosomal system. Journal of Cell Science 136 (6) jcs259875. (10.1242/jcs.259875)
- Vruchte, D. T. et al., 2004. Accumulation of glycosphingolipids in Niemann-Pick C disease disrupts endosomal transport. Journal of Biological Chemistry 279 (25), pp.26167-26175. (10.1074/jbc.M311591200)
- Walker, M. W. and Lloyd-Evans, E. 2015. A rapid method for the preparation of ultrapure, functional lysosomes using functionalized superparamagnetic iron oxide nanoparticles. Methods in Cell Biology 126 , pp.21-43. (10.1016/bs.mcb.2014.10.019)
- Waller-Evans, H. and Lloyd-Evans, E. 2015. Regulation of TRPML1 function. Biochemical Society Transactions 43 (3), pp.442-446. (10.1042/BST20140311)
- Williamson, L. J. et al. 2023. Structure of the Lysinibacillus sphaericus Tpp49Aa1 pesticidal protein elucidated from natural crystals using MHz-SFX. Proceedings of the National Academy of Sciences 120 (49) e2203241120. (10.1073/pnas.2203241120)
Book sections
- Kirkham, E. et al., 2025. Lysosomal pH measurements via dual-imaging microscopy. In: Hughes, S. M. and Basak, I. eds. Lysosomes: Methods and Protocols. Vol. 2976, Methods in Molecular Biology New York, New York, USA: , pp.11-24. (10.1007/978-1-0716-4844-5_2)
Conferences
- Best, H. et al. 2023. The Batten disease associated protein CLN3 is required for the efflux of lysosomal K. Presented at: 19th Annual WORLDSymposium™ 2023 Orlando, Florida 21-26 February 2023. Vol. 138.Vol. 2. Elsevier. , pp.47-47. (10.1016/j.ymgme.2022.107030)
- Best, H. L. et al. 2023. Disease phenotypes present in CLN7 patient fibroblasts are improved following treatment to reduce glycosphingolipid synthesis.. Presented at: 19th Annual WORLDSymposium™ 2023 Orlando, Florida 21-26 February 2023. Vol. 138.Vol. 2. Elsevier. , pp.17. (10.1016/j.ymgme.2022.107029)
- Cook, S. R. et al. 2023. Investigating lysosomal and cellular phenotypes of the lysosomal disorder cystinosis. Presented at: 19th Annual WORLDSymposium™ 2023 Orlando, Florida 21-26 February 2023. Vol. 138.Vol. 2. Elsevier. , pp.28-28. (10.1016/j.ymgme.2022.107061)
- Cook, S. R. and Lloyd-Evans, E. 2023. Comparing the lysosomal biotoxicity of iron oxide nanoparticles for improved lysosomal purification. Presented at: 19th Annual WORLDSymposiumTM Orlando, Florida 21-26 February 2023. Vol. 138.Vol. 2. Elsevier. , pp.28-29. (10.1016/j.ymgme.2022.107062)
- Fenn, G. D. , Lloyd-Evans, E. and Waller-Evans, H. 2023. Investigation of cannabidiol as a potential therapeutic in Niemann-Pick disease. Presented at: 19th Annual WORLDSymposium™ 2023 Orlando, Florida 21-26 February 2023. Vol. 138.Vol. 2. Elsevier. , pp.42-42. (10.1016/j.ymgme.2022.107098)
- Honeybun, L. , Waller-Evans, H. and Lloyd-Evans, E. 2023. Unbiased phenotypic drug screen for CLN3 disease. Presented at: 19th Annual WORLDSymposium™ 2023 Orlando, Florida 21-26 February 2023. Vol. 138.Vol. 2. Elsevier. , pp.167-167. (10.1016/j.ymgme.2022.107150)
- Lloyd-Evans, E. et al. 2023. Glycosphingolipid reduction with miglustat as a therapeutic strategy for CLN3 and other neuronal ceroid lipofuscinoses.. Presented at: 19th Annual WORLDSymposium™ 2023 Orlando, Florida 21-26 February 2023. Vol. 138.Vol. 2. Elsevier. , pp.84. (10.1016/j.ymgme.2022.107212)
- Lloyd-Evans, E. and Evans, C. 2023. Deciphering the various mechanisms of action of miglustat in the lysosomal disorders.. Presented at: 19th Annual WORLDSymposiumTM Orlando, Florida 21-26 February 2023. Vol. 138.Vol. 2. Elsevier. , pp.84. (10.1016/j.ymgme.2022.107213)
- Waller-Evans, H. et al. 2023. Filipin composition and imaging modality dramatically affect cellular cholesterol visualisation with implications for assessing cholesterol levels and localisation across the lysosomal disorders. Presented at: 19th Annual WORLDSymposium™ 2023 Orlando, Florida 21-26 February 2023. Vol. 138.Vol. 2. Elsevier. , pp.133. (10.1016/j.ymgme.2022.107352)
- Waller-Evans, H. et al. 2023. Measuring ion flux via lysosomal channels: Primary and secondary assays for drug discovery across the lysosomal disorders. Presented at: 19th Annual WORLDSymposium™ 2023 Orlando, Florida 21-26 February 2023. Vol. 138.Vol. 2. Elsevier. , pp.133-134. (10.1016/j.ymgme.2022.107353)
Research
Our current interests
- We are currently interrogating a number of lysosomal targets within the group and in collaboration with others at the MDI (Dr. Helen Waller-Evans & Dr. D. Heulyn Jones), this includes the utilisation of high throughput biochemical assays, medicinal chemistry, structural biology, drug metabolism and pharmacokinetics through to iPS derived neuronal and microglial cellular models of disease.
- Fundamental research projects include:
- The characterisation of novel lysosomal ion channels and the identification of novel tool compounds to modulate their function.
- Development of phenotypic assays for enabling high throughput compound screening both internally and externally.
- The characterisation of lipid storage and lysosomal dysfunction in DHDDS (funded by CureDHDDS).
- The development of AI based approaches to enable lysosomal ion channel drug discovery.
- Prof. Lloyd-Evans is co-I on the MDI-Astex collaborative project.
For further more detailed information on projects please visit our external group websites:
Medicines discovery instituteLloyd-Evans lab group members:
- Dr. Sophie Cook (Research Fellow)
- Dr. Hannah Best (Post-doc)
- Dr. Gaia Pasqualetto (Research Assistant)
- Ms Llinos Honeybun (PhD student)
- Mr Iwan Williams (PhD student)
- Mr Tom Duffy (PhD student)
Lloyd-Evans lab resources:
In addition to the world class facilities and truly multi-disciplinary nature of the MDI, the ELE lab also has numerous unique and cutting edge microscopes for high throughput and high speed confocal imaging alongside real time LED based Ca2+ and other ion imaging systems. We have also established a centre of excellence in automated electrophysiology and patch clamping (including the Nanion Patchliner, port-a-patch, Orbit and SURFE2R systems) and are the only centre with this automated ephys capacity across the GW4 consortium.
Lloyd-Evans lab funding:
We have been funded by MRC, BBSRC and ERC as well as numerous charities and companies. Current funding is from companies, MRC IAA, CureDHDDS, Action Medical Research, BBSRC SWBio DTP and the Coleg Cymraeg Cenedlaethol.
Joining us:
We are always interested in supporting external applications for fellowships or PhDs, please contact Prof. Lloyd-Evans to discuss.
Biography
My first degree was an undergraduate masters in Biochemistry (M.Biochem) at the University of Bath. During this degree I spent 11 months (2 successive placements) in the lab of Prof. Tony Futerman at the Weizmann Institute of Science, Rehovot, Israel. It was here that I gained an interest in lysosomal storage diseases, researching the role of altered endoplasmic reticulum Ca2+ homeostasis in Gaucher disease. Following my degree in 2002 I moved to Oxford to do my DPhil with Prof. Fran Platt at the Glycobiology Institute. Here I researched the role of the simple sphingolipid sphingosine in the pathogenesis of Niemann-Pick type C1. Upon completion of my DPhil In 2005, I moved with Fran to the Department of Pharmacology (Oxford) where, in collaboration with Prof. Antony Galione, we developed techniques to study lysosomal Ca2+ homeostasis in the lysosomal diseases. In 2010 I was appointed as an RCUK Fellow at the School of Biosciences, Cardiff University, to continue my research into lysosomal function.
